TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04552106

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 3 caps x2/day
Description: 3 capsules 2 times daily for 28 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 2 caps x3/day
Description: 2 capsules 3 times daily for 28 days
Study: NCT03675282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (11C)PE2I
Description: Subjects will received (11C)PE2I PET Scans at Baseline and 24 Month Visits

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (11C)PE2I
Description: Subjects will received (11C)PE2I PET Scans at Baseline and 24 Month Visits

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (11C)PE2I
Description: Subjects will received (11C)PE2I PET Scans at Baseline and 24 Month Visits
Study: NCT04552106

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 2 caps x2/day
Description: 2 capsules 2 times daily for 28 days
Study: NCT03675282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (11C)PE2I
Description: Subjects will received (11C)PE2I PET Scans at Baseline and 24 Month Visits

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (11C)PE2I
Description: Subjects will received (11C)PE2I PET Scans at Baseline and 24 Month Visits

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (11C)PE2I
Description: Subjects will received (11C)PE2I PET Scans at Baseline and 24 Month Visits

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ioflupane
Description: Subjects will receive a DaT scan at baseline and 24 month visits if they don't receive a PE2I PET scan at baseline and 24 month visits

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ioflupane
Description: Subjects will receive a DaT scan at baseline and 24 month visits if they don't receive a PE2I PET scan at baseline and 24 month visits

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ioflupane
Description: Subjects will receive a DaT scan at baseline and 24 month visits if they don't receive a PE2I PET scan at baseline and 24 month visits

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ioflupane
Description: Subjects will receive a DaT scan at baseline and 24 month visits if they don't receive a PE2I PET scan at baseline and 24 month visits
Study: NCT04552106

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 3 caps x1/day
Description: 3 capsules 1 times daily for 28 days
Study: NCT01227863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAXINOM®
Description: Dexamethasone...............................................0,1% Neomicyn......................................0,35% polimixyn B...................................0,1%
Study: NCT02606591

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Tests
Description: During the EEG, participant asked to wear headphones and do some simple tests on the computer that measure their abilities to see, hear, and understand information.
Study: NCT03675282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ioflupane
Description: Subjects will receive a DaT scan at baseline and 24 month visits if they don't receive a PE2I PET scan at baseline and 24 month visits
Study: NCT02606591

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hair Sample
Description: Participants provide a sample of hair at baseline (near the beginning of school), and follow-up (near the end of school). Sample tested to measure cortisol levels.
Study: NCT00539838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral repeating dose
Study: NCT00539838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate)
Description: Oral repeating dose
Study: NCT03738826

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Lupus clinic providers will be prompted to assess adherence level using Surescripts refill information and address any adherence barriers that arise during the clinical encounter.
Study: NCT03331978

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rise - Treatment Education
Description: Rise consists of a one-month intensive intervention (with three core 60-minute counseling sessions at weeks 1, 2, and 4) followed by two booster sessions (at weeks 12 and 20). If participants show nonadherence during booster sessions, they are offered up to four additional booster sessions (i.e., extra booster sessions if \<85% of prescribed doses were taken in the past month). Thus, participants receive three core sessions in the first month, followed by 2-6 booster sessions over the next four months.
Study: NCT02359071

Intervention type: OTHER
Intervention: handover duration, handover rate
Description: To better analyze independent variables, we dichotomized the data. First, we dichotomized handover duration into two groups according to the median handoff time of 20 minutes. Second, we divided handover rates into two groups using the median rate of handovers per shift, which was 3.87%.

Intervention type: OTHER
Intervention: handover duration, handover rate
Description: To better analyze independent variables, we dichotomized the data. First, we dichotomized handover duration into two groups according to the median handoff time of 20 minutes. Second, we divided handover rates into two groups using the median rate of handovers per shift, which was 3.87%.
Study: NCT03822897

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiation
Description: 35 fractions, 5/wk, 7 wks 70Gy/56Gy, or~35 fractions, 6/wk, 6 wks, 70Gy/56Gy, or~35 fractions, 5/wk, 7 wks OR 6/wk, 6 wks 70Gy/56Gy
Study: NCT04828733

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic one anastomosis gastric bypass with excluded stomach fundoplication: FundoRingOAGB and suture cruroplasty
Description: Laparoscopic gastric bypass with suture cruroplasty and excluded stomach fundoplication use FundoRing method.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic one anastomosis gastric bypass with excluded stomach Nissen fundoplication and suture cruroplasty
Description: Laparoscopic gastric bypass with suture cruroplasty and excluded stomach fundoplication use the Nissen method.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard laparoscopic one anastomosis gastric bypass with cruroplasty. Not used fundoplication.
Description: Laparoscopic gastric bypass with only suture cruroplasty without fundoplication
Study: NCT04639466

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given IM in the non-dominant upper arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given IM in the non-dominant upper arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1
Description: Given IM in the non-dominant upper arm

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1
Description: Given IM in the non-dominant upper arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1
Description: Given IM in the non-dominant upper arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1
Description: Given IM in the non-dominant upper arm
Study: NCT03822897

Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: 100 mg/m2 on day 1, 22, and 43 or 40 mg/m2 /wk for 7 wks
Study: NCT03559777

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: closed sinus lifting by Osteotome
Description: * Local anesthesia will be injected intra-orally~* A full thickness flap will be elevated~* A pilot drill will be used to start the osteotomy preparation, which should be ended 1mm short of sinus floor.~* The widening drills can be sequentially used to widen the osteotomy site to the same level~* An osteotome of diameter a little less than the planned implant body, will be inserted in the prepared osteotomy site and gently tapped to reach the same level.~* The osteotome will be tapped gently to fracture up the sinus floor.~* Xenograft will be added to the osteotomy as the grafting material.~* Once the desired height of sinus elevation will be gained and grafted, the implant fixture will be inserted.~* Smart peg will be placed on implant and Ostell will be used to record ISQ.~* Healing collar will be placed on implant.~* Suturing the flab around healing collar.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: closed sinus lifting by Densah bur
Description: * Local anesthesia will be injected intra-orally~* A full thickness flap will be elevated~* A pilot drill will be used to start the osteotomy , which should be ended 1mm short of sinus floor.~* Change the drill motor to reverse- densifying Mode~* with the densah bur (2.5mm) until 1 mm short of the sinus floor.~* Use the next wider Densah Bur (3.0) in densifying-mode until feeling the haptic feedback of the bur reaching the dense sinus floor, modulate pressure with a gentle pumping motion to advance past the sinus floor in 1 mm increments.~* densah burs (3.5mm) advance in the osteotomy.~* Xenograft will be added to the osteotomy .~* Once the desired height of sinus elevation will be gained and grafted, the implant fixture will be inserted.~* Smart peg will be placed on implant and Ostell will be used to record ISQ.~* Healing collar will be placed on implant.~* Suturing the flab around healing collar.
Study: NCT03368105

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prevention of C. difficile infections using LP299v strain
Description: Patients treated with antibiotics and at high CDI risk (patients after organ transplantation or receiving immunosuppressive therapy for any other reason) will be enroll to study.~We will divide participants into two group. Group 1 will receive one capsule of LP299v orally per a day during the entire period of antibiotic therapy. Group 2 will receive one capsule of placebo during the entire period of antibiotic therapy.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Prevention of C. difficile infections using LP299v strain
Description: Patients treated with antibiotics and at high CDI risk (patients after organ transplantation or receiving immunosuppressive therapy for any other reason) will be enroll to study.~We will divide participants into two group. Group 1 will receive one capsule of LP299v orally per a day during the entire period of antibiotic therapy. Group 2 will receive one capsule of placebo during the entire period of antibiotic therapy.
Study: NCT03880162

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet
Description: A energy deficient (30% deficit) low carbohydrate diet (10% of carbohydrates)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Energy-matched standard diet
Description: Energy-matched (30% deficit) standard diet (50% of carbohydrates)
Study: NCT04589260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1058
Description: Study drug to be administered by oral inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to be administered by oral inhalation
Study: NCT04278456

Intervention type: BEHAVIORAL
Intervention: postpartum depression
Description: melatonin levels in c-sections with different anesthesia modalities.
Study: NCT02803866

Intervention type: BEHAVIORAL
Intervention: Training program CAP-PREM
Description: 1ºAfter recruitment parents will fill the PMP S-E tool and the psychological tests evaluating their stress and depression . 2º parents will receive the training program during 4 weeks. 3º: before hospital discharge parents will fill again the PMP S-E tool and the psychological test evaluating their depression and anxiety
Study: NCT02708498

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: The seminar groups will be led by two experienced clinical nurses and researchers from the field of palliative care and geriatric care. The educational material consist of six themes; values in palliative care, symptom relief, dignity and a dignified death, collaborative co-creating care, support to next of kin and dialogue with older persons and next of kin about death and dying. The content of the different themes will have a common core for each nursing home but will be adjusted based on the expressed needs of each nursing home. New themes can be created related to the needs of the unique nursing home. The participants in the seminar groups will reflect together over the content of the developed binder of educational material and will relate it to their own work in order to identify areas suitable for changes and/or development.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: The seminar groups will be led by two experienced clinical nurses and researchers from the field of palliative care and geriatric care. The educational material consist of six themes; values in palliative care, symptom relief, dignity and a dignified death, collaborative co-creating care, support to next of kin and dialogue with older persons and next of kin about death and dying. The content of the different themes will have a common core for each nursing home but will be adjusted based on the expressed needs of each nursing home. New themes can be created related to the needs of the unique nursing home. The participants in the seminar groups will reflect together over the content of the developed binder of educational material and will relate it to their own work in order to identify areas suitable for changes and/or development.
Study: NCT01558726

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case Management (Strength-Based)
Description: To improve the cases sharing between CAPSad and other health institutions and individuals and increase the strengths of the patient to cope with problems related to the crack use.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Treatment
Description: The usual treatment used for regular patients of CAPSad
Study: NCT00505024

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Voice Response System
Description: Calls twice weekly, where the system will ask you to rate types of symptoms on a scale from 0 to 10.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Voice Response System
Description: Calls twice weekly, where the system will ask you to rate types of symptoms on a scale from 0 to 10.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptoms Report
Description: A report of severe symptoms will be sent to your doctor or nurse.
Study: NCT03945084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered as a flat-fixed, continuous daily dose:~≥77 kg and ≥150,000 µL: 300 mg (3 X 100 mg capsules) daily \<77 kg or \<150,000 µL: 200 mg (2 X 100 mg capsules) daily\*~\* For patients whose starting dose is 2 capsules once daily, escalation to 3 capsules once daily will be permitted if no treatment interruption or discontinuation will be required during the first 2 cycles of therapy

Intervention type: OTHER
Group type: OTHER
Intervention: Best supportive care
Description: In both treatment arms, Best Supportive Care (BSC) is defined as a comprehensive assessment of symptoms, with timely application of symptom control measures, in order to maximize patient's quality of life.~BSC does not include any active antitumoral treatment, and will be given according to local guidelines and the normal practice of each participating institution.~BSC will include use of opioid analgesics, other supportive drugs, radiotherapy, administered with the exclusive aim of improving tumor symptoms (e.g. pain, haematuria, etc.), according to Investigator's judgment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best supportive care
Description: In both treatment arms, Best Supportive Care (BSC) is defined as a comprehensive assessment of symptoms, with timely application of symptom control measures, in order to maximize patient's quality of life.~BSC does not include any active antitumoral treatment, and will be given according to local guidelines and the normal practice of each participating institution.~BSC will include use of opioid analgesics, other supportive drugs, radiotherapy, administered with the exclusive aim of improving tumor symptoms (e.g. pain, haematuria, etc.), according to Investigator's judgment.
Study: NCT04510493

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Canakinumab
Description: Body weight adjusted dose in 250 ml 5% dextrose solution i.v. over 2 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Aqua ad injectabilia in 250 ml 5% dextrose solution i.v. over 2 hours
Study: NCT02346409

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS of the cerebellum
Description: tACS of the cerebellum

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tACS of the cerebellum
Description: tACS of the cerebellum
Study: NCT01900015

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.
Study: NCT03660527

Intervention type: OTHER
Intervention: Not refered
Description: No intervention was refered.

Intervention type: OTHER
Intervention: Not refered
Description: No intervention was refered.

Intervention type: OTHER
Intervention: Not refered
Description: No intervention was refered.

Intervention type: OTHER
Intervention: Not refered
Description: No intervention was refered.
Study: NCT00774826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CVP
Description: Rituximab: 375 mg/mq day 1 Ciclofosfamide: 750 mg/mq day 1, Vincristina: 1,4 mg/mq day 1 Prednisone: 40 mg/mq day 1-5,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOP
Description: Rituximab: 375 mg/mq day 1 Ciclofosfamide: 750 mg/mq day 1 Doxorubicina: 50 mg/mq day 1 Vincristina: 1.4 mg/mq day 1 Prednisone: 100 mg/mq day 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-FM
Description: Rituximab: 375 mg/mq day 1, Fludarabina: 25 mg/mq day 1-3, Mitoxantrone: 10 mg/mq day 1,
Study: NCT01482091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Citrate
Description: A single dose of fentanyl citrate (2 mcg/kg; max 100mcg) administered intranasally. Half of the volume will be administered in each nare. The medication will be administered using a mucosal atomization device

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: A single dose of equivalent volume of 0.9% Normal Saline will be administered intranasally. Half of the volume will be administered in each nare. The medication will be administered using a mucosal atomization device.
Study: NCT02382419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carrageenan-containing gel
Description: Applied vaginally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Applied vaginally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00539838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate)
Description: Oral repeating dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate)
Description: Oral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous repeating dose
Study: NCT03974230

Intervention type: OTHER
Intervention: Collection of datas
Description: Collection of datas of examination for diagnosis and follow-up of the Fuchs Endothelial Corneal Dystrophy (FECD) including slit lamp results will be performed.

Intervention type: BIOLOGICAL
Intervention: blood sample
Description: Blood sample will be performed (genetic analyses).

Intervention type: BIOLOGICAL
Intervention: blood sample
Description: Blood sample will be performed (genetic analyses).
Study: NCT04278456

Intervention type: BEHAVIORAL
Intervention: postpartum depression
Description: melatonin levels in c-sections with different anesthesia modalities.

Intervention type: BEHAVIORAL
Intervention: postpartum depression
Description: melatonin levels in c-sections with different anesthesia modalities.
Study: NCT00911300

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fondaparinux
Description: Comparison of different drugs
Study: NCT03974230

Intervention type: OTHER
Intervention: slit lamp examination
Description: Slit lamp examination will be performed.
Study: NCT00880529

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ON-Q bupivicaine administration
Description: continuous subcutaneous bupivicaine drip

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV opioid administration
Description: Patient controlled analgesia with IV narcotics
Study: NCT00805792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Study participants will be treated with donepezil orally at an initial dose of 5 mg daily for the first 4 weeks, then increased at their 30-day visit by 5 mg to a maximum dose of 10 mg daily, if tolerated. If the participant does not tolerate the 10 mg dose, they will remain on 5 mg through the course of the study.
Study: NCT02382419

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03164304

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: intravenous